DrugPatentWatch Database Preview
Panitumumab - Biologic Drug Details
» See Plans and Pricing
Summary for panitumumab
| Tradenames: | 1 |
| Patents: | 346 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for panitumumab |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for panitumumab |
Recent Clinical Trials for panitumumab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Stanford University | Phase 1/Phase 2 |
| University of Wisconsin, Madison | Phase 2 |
| Doris Duke Charitable Foundation | Phase 2 |
Recent Litigation for panitumumab
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Ravgen, Inc. v. Illumina, Inc. | 2020-12-02 |
| IMMUNEX CORPORATION v. SAMSUNG BIOEPIS CO., LTD. | 2019-04-30 |
| Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc. | 2013-10-08 |
See all panitumumab litigation
PTAB Litigation
| Petitioner | Date |
|---|---|
| GEMoaB Monoclonals GmbH | 2019-12-20 |
| 2018-03-20 | |
| Forty Seven, Inc. | 2018-01-08 |
Pharmacology for panitumumab
| Ingredient-type | Antibodies, Monoclonal |
| Mechanism of Action | HER1 Antagonists |
Company Disclosures: US Patents for panitumumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | Abgenix, Inc. (Fremont, CA) | 2039-02-26 | RX | company | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | Amgen Fremont Inc. (Fremont, CA) | 2017-05-05 | RX | company | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 002 | 2006-09-27 | Start Trial | Abgenix, Inc. (Fremont, CA) | 2039-02-26 | RX | company | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for panitumumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | VentiRx Pharmaceuticals, Inc. (Seattle, WA) | 2030-04-21 | RX | search | |
| Amgen | VECTIBIX | panitumumab | INJECTABLE; IV (INFUSION) | 125147 | 001 | 2006-09-27 | Start Trial | University of Georgia Research Foundation, Inc. (Athens, GA) | 2039-02-26 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for panitumumab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2765727 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2014152795 | Start Trial |
| Israel | 241827 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for panitumumab
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 4 | Finland | Start Trial | |
| 411 | Luxembourg | Start Trial | 91411, EXPIRES: 20221203 |
| C0022 | France | Start Trial | PRODUCT NAME: PANITUMUMAB; REGISTRATION NO/DATE IN FRANCE: EU/1/07/423/001 DU 20071203; REGISTRATION NO/DATE AT EEC: EU/1/07/423/001 DU 20071203 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
